Medicine
Perioperative Management of Anticoagulation in Elective Surgery
Quick fact
For most direct oral anticoagulants (DOACs), surgery is typically postponed until 24 to 72 hours after the last dose, depending on the drug and kidney function, while warfarin is usually stopped about 5 days before surgery—but some patients need 'bridging' with a short-acting injectable anticoagulant to keep them protected.
Why this is interesting
Imagine you're scheduled for a minor surgery, but you take a daily blood thinner. Your doctor says you must stop it—but how long before? Too long and you risk a blood clot; too short and you risk bleeding on the operating table. How do they decide?
Read the full explanation
Understanding Perioperative Management of Anticoagulation in Elective Surgery
Anticoagulants are medications that reduce the blood's ability to form clots. They are used to prevent strokes in atrial fibrillation, to treat deep vein thrombosis, and to prevent clots around mechanical heart valves. But when you need surgery, the surgeon needs to make an incision, which will bleed. If your blood is too thin, you could bleed excessively. So we must temporarily stop the anticoagulant. The challenge is that stopping the drug also removes the protection against dangerous blood clots. The goal is to find a 'sweet spot': a window of time where the anticoagulant effect is low enough to allow surgery safely, but not so long that the patient is unprotected. The management plan involves two risks: the risk of postoperative bleeding and the risk of a perioperative thromboembolic event. The decision is individualized based on the type of anticoagulant, the patient's kidney function, the reason for anticoagulation (e.g., mechanical mitral valve vs. atrial fibrillation), and the type of surgery (minor vs. major). For patients at high risk of blood clots, a technique called 'bridging' is used: before surgery, the long-acting anticoagulant (e.g., warfarin) is stopped, and a short-acting injectable (e.g., enoxaparin) is given until the day of surgery. After surgery, the injectable is restarted as soon as bleeding risk allows, and the original anticoagulant is resumed. For DOACs, which have short half-lives, bridging is rarely needed.
A deeper explanation
The underlying principle is the balance between hemostasis (clot formation to stop bleeding) and thrombosis (clot formation that blocks vessels). Anticoagulants work by inhibiting specific clotting factors. Warfarin inhibits vitamin K-dependent factors (II, VII, IX, X) and has a long half-life, so its effect lasts for days. DOACs like dabigatran, rivaroxaban, and apixaban directly target single factors (thrombin or factor Xa) and have shorter half-lives, typically 5–15 hours, largely cleared by the kidneys. In elective surgery, we deliberately allow the anticoagulant effect to wear off. For warfarin, the international normalized ratio (INR) is used to measure its effect; surgery is generally safe when INR is ≤1.5. Stopping warfarin 5 days before surgery generally brings the INR down. For DOACs, the timing is based on half-life and renal function; for instance, with normal kidneys, a drug with a 12-hour half-life needs about 2–3 days off (roughly 4–5 half-lives) to reach <12% of peak effect. The plan must also consider that surgery causes tissue trauma, which triggers a prothrombotic state. Therefore, the postoperative period is high-risk for both bleeding and clotting. Bridging with short-acting agents minimizes the time without protection and allows rapid reversal if needed. This whole process is a dynamic risk-balancing exercise that requires close coordination between the patient, the surgical team, and the prescribing clinician.